Neurofibromatosis Type 1 Market Report 2026

The neurofibromatosis type 1 market size has grown strongly in recent years. It will grow from $8.83 billion in 2025 to $9.68 billion in 2026 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to early identification of nf1 symptoms, development of pain management treatments, increased diagnosis of plexiform neurofibromas, adoption of surgical tumor removal, rising awareness of genetic counseling.

The neurofibromatosis type 1 market size is expected to see strong growth in the next few years. It will grow to $13.78 billion in 2030 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to growing demand for targeted nf1 therapies, rising investment in precision oncology, expansion of optic glioma treatment options, increasing availability of advanced imaging tools, development of novel gene-based treatments. Major trends in the forecast period include increasing use of targeted therapy for tumor reduction, growing demand for early nf1 genetic testing, expansion of surgical interventions for tumor removal, rising adoption of radiation therapy for optic gliomas, increasing focus on supportive care and counseling services.

Spontaneous (de novo) mutations are expected to drive the growth of the neurofibromatosis type 1 (NF1) market in the coming years. A spontaneous (de novo) mutation is a genetic change that occurs for the first time in an individual due to errors in DNA replication or environmental influences, rather than being inherited from parents. The rise in these mutations is linked to factors such as increased parental age, environmental exposures like radiation and chemicals, and replication errors during cell division. Neurofibromatosis type 1 (NF1) is associated with a high mutation rate in the NF1 gene, which often undergoes large deletions, insertions, or point mutations during gametogenesis, leading to new cases without a family history. For example, in August 2023, a report published by Molecular Biology and Evolution, a US-based peer-reviewed journal, identified 1.17 million autosomal and pseudoautosomal variants, averaging 11,007 variants per offspring. Among these, 534 putative de novo mutations (DNMs) were detected in POR and TVA families, excluding variants shared among siblings. Therefore, spontaneous (de novo) mutations are contributing significantly to the growth of the NF1 market.

Companies in the neurofibromatosis type 1 (NF1) market are increasingly focusing on introducing innovative therapies such as kinase inhibitors to enhance targeted treatment and patient outcomes. Kinase inhibitors are drugs that block the activity of kinases - enzymes responsible for transferring phosphate groups to proteins - thereby regulating critical cellular processes. For instance, in May 2023, AstraZeneca plc, a UK-based pharmaceutical company, received approval in China for Koselugo (selumetinib), indicated for treating symptomatic, inoperable plexiform neurofibromas (PN) in pediatric patients aged three years and older with NF1. This approval expands targeted treatment options for pediatric NF1 patients, improving disease management and quality of life. The introduction of Koselugo (selumetinib) in China underscores the growing focus on precision medicine, providing a non-surgical approach for managing inoperable plexiform neurofibromas.

In July 2025, Merck KGaA, a Germany-based science and technology company, acquired SpringWorks Therapeutics for $3.4 billion. Through this acquisition, Merck KGaA aims to broaden its rare tumor portfolio and reinforce its global oncology strategy by integrating SpringWorks’ FDA-approved therapies for desmoid tumors and NF1-associated plexiform neurofibromas. SpringWorks Therapeutics is a US-based developer of targeted therapies for rare tumors and genetically defined cancers, including approved treatments for desmoid tumors and NF1-related plexiform neurofibromas.

Major companies operating in the neurofibromatosis type 1 market are Pfizer Inc, F. Hoffmann-La Roche Ltd, Merck & Co. Inc, Novartis AG, Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Incorporated, BeiGene Ltd, BioMarin Pharmaceutical Inc, Blueprint Medicines Corporation, SpringWorks Therapeutics Inc, Healx Limited, Infixion Bioscience Limited, NFlection Therapeutics Inc, Pasithea Therapeutics Corporation, Mulberry Biotherapeutics Inc, CureAge Therapeutics, Fosun Pharmaceutical Group Co Ltd, AstraZeneca Plc, Genentech Inc, Regeneron Pharmaceuticals Inc, Amgen Inc, AbbVie Inc, GL Pharm Tech Corporation, ReCode Therapeutics Inc.

North America was the largest region in the neurofibromatosis type 1 (NF1) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurofibromatosis type 1 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the neurofibromatosis type 1 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the neurofibromatosis type 1(nf1) market by increasing the costs of imported targeted therapy drugs, diagnostic materials, and radiation treatment equipment required for managing tumor growth and nerve-related complications. These added costs particularly affect hospitals, specialty clinics, and ambulatory centers in regions dependent on imported oncology pharmaceuticals such as Europe and Asia-Pacific. Treatment categories involving targeted therapy, radiation therapy, and genetic testing face procurement delays and higher operating expenses. However, tariffs are encouraging regional production of oncology drugs, strengthening local supply chains, and promoting investment in cost-effective NF1 care solutions.

The neurofibromatosis type 1 market research report is one of a series of new reports that provides neurofibromatosis type 1 market statistics, including neurofibromatosis type 1 industry global market size, regional shares, competitors with a neurofibromatosis type 1 market share, detailed neurofibromatosis type 1 market segments, market trends and opportunities, and any further data you may need to thrive in the neurofibromatosis type 1 industry. This neurofibromatosis type 1 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Neurofibromatosis type 1 (NF1) is a genetic disorder that primarily impacts the nervous system, leading to the growth of benign tumors along nerves in the skin, brain, and other areas of the body. It results from mutations in the NF1 gene, causing a deficiency of neurofibromin, a protein that regulates cell growth. This deficiency leads to a range of symptoms, including café-au-lait spots (light brown skin patches), freckling in unusual areas, learning difficulties, skeletal abnormalities, and, in some cases, vision or nerve-related complications.

The primary treatments for neurofibromatosis type 1 (NF1) include medication, surgery, radiation therapy, and other interventions. Medications for NF1 consist of pharmaceutical options such as MEK inhibitors, pain relievers, and antihypertensive drugs, which aim to reduce tumor growth, control pain, and manage complications. The disease manifests in forms such as plexiform neurofibromas, cutaneous neurofibromas, optic gliomas, and other related conditions. These treatments are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and are utilized by various end-users, including hospitals, specialty clinics, ambulatory surgical centers, and other healthcare facilities.

The neurofibromatosis type 1 (NF1) market consists of revenues earned by entities by providing services such as medical monitoring, genetic counselling, and specialized care. The market value includes the value of related goods sold by the service provider or included within the service offering. The neurofibromatosis type 1 (NF1) market also includes sales of medical devices, MEK inhibitors, anticonvulsants, and analgesics. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.